Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Search
Patient Assistance Program
Patient Assistance Program
Results from Phase II MASH trial announced at EASL 2024
Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024
BI Cares Patient Assistance Program
BI Cares Patient Assistance Program
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Ruminants
Ruminants
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US
Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).
Thinking differently could eradicate some areas of retinal disease
Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
SPEVIGO approved for expanded indications in China and the US
FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
BI Starts Clinical Study on Interchangeability | Boehringer Ingelheim US
BI announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study, for an adalimumab biosimilar candidate.
Fostering Science | Boehringer Ingelheim US
Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.
Could decentralised trials transform the way we view depression?
Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.
Innovation in Immunology | Human Health | Boehringer Ingelheim US
BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US
FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.
BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US
FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Human Health Products
Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.
Innovation in Oncology and Cancer Immunology
Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials